Table 3.
State of clinical use
| Wild-type (n = 398) | Heterozygous (n = 327) | Homozygous (n = 70) | |
|---|---|---|---|
| Starting dose (mg/m2) | |||
| CPT-11, median (range) | 143.0 (56–185) | 143.0 (23–181) | 115.0 (41–180) |
| Bolus 5-FU, median (range) | 384.0 (0–796) | 380.0 (0–800) | 383.5 (0–517) |
| Infusional 5-FU, median (range) | 2327.0 (538–2542) | 2312.0 (178–2830) | 2299.0 (0–2469) |
| Distribution of starting CPT-11 dose | |||
| <142.5 mg/m2 (%) | 194 (48.7) | 163 (49.8) | 47 (67.1) |
| ≥142.5 mg/m2 (%) | 204 (51.3) | 164 (50.2) | 23 (32.9) |
CPT-11 irinotecan, 5-FU 5-fluorouracil